E5564, a lipid A analogue, is a potent antagonist of lipopolysaccharide (LPS). Clinically, E5564 was developed as a possible therapy for treatment of sepsis and septic shock. Surface plasmon resonance (SPR) analysis indicates that E5564 binds to LPS binding protein (LBP), in a manner similar to LPS. Gel-filtration radioactive chromatograms of [
INTRODUCTION
Lipopolysaccharide (LPS), a component of the outer membrane of many pathogenic Gram-negative bacteria, stimulates the release of pro-inflammatory mediators, such as interleukin (IL)-1, IL-6, IL-8, and tumor necrosis factor (TNF), by macrophages, monocytes, and other immune cells.
1 LPS contains three distinct domains: the lipid A domain, the oligosaccharide core of heptose and 3-deoxy-D-manno-2-octulosonic acid, and an O-antigenic polysaccharide domain. 2 The lipid A region backbone, essential for LPS-associated pro-inflammatory toxicity, contains two phosphorylated glucosamine molecules acylated by 4-6 fatty acids. 3, 4 Both LPS and the lipid A portion from certain non-enterobacterial species, such as Rhodobacter capsulatus 5 and R. sphaeroides, [6] [7] [8] only weakly stimulate cytokine release from monocytes and macrophages. Lipid A compounds from both species exhibit anti-endotoxin activity in vivo and in vitro with a potency that would prove useful as pharmaceutical LPS antagonists. E5564 is a second generation synthetic lipid A analogue bearing similarity to R. sphaeroides lipid A. 9, 10 In vitro studies of human blood demonstrate that, although E5564 antagonizes LPS-mediated release of humoral mediators, it is devoid of any immune cell agonistic activity. E5564 blocks the effects of endotoxin in human models of clinical sepsis, indicating its potential for the treatment of sepsis. 10, 11 Single intravenous administration pharmacokinetics in human, rats and dogs indicates slow plasma clearance of E5564. 12, 13 Also, a tissue distribution study in rats following intravenous administration of [ 14 
C]-E5564
A detailed study conducted in rabbits demonstrated that while LPS is first taken up by the liver, spleen, and lungs after administration, the radioactivity derived from LPS accumulates in the adrenal glands during the distribution phase. 15 Although the distribution of radioactivity derived from [ 14 C]-E5564 to these tissues occurs on a slower time-scale than seen with LPS, the mechanism underlying this difference remains unclear.
Pre-mixing LPS with HDL enhances the redistribution of radioactivity to the adrenal glands, 16 the organ containing cells expressing the HDL receptor, lipid scavenger receptor B1. 17 Also, chylomicron increases the clearance of LPS by the liver, due to increases in hepatocyte, rather than Kupffer cell, uptake. 18 These data suggest that binding of LPS to lipoprotein classes is important for clearance in vivo. As it is likely that the binding to lipoproteins functions in the clearance of E5564 in a manner similar to LPS, we sought to determine the binding profile of E5564 to lipoproteins to better understand its pharmacokinetic behavior.
Among the many methods to evaluate the interactions between LPS and plasma proteins, [19] [20] [21] [22] [23] gel-filtration chromatography (GFC) is frequently used. 24, 25 We utilized high-performance gel-filtration liquid chromatography (GFC-HPLC), because this method provides a rapid analysis capable of evaluating the time-dependent kinetics of the distribution and binding of E5564 to lipoproteins in plasma.
As LBP performs a key function in the binding of LPS to lipoproteins, we also evaluated the binding of LBP to E5564 using surface plasmon resonance (SPR) 26, 27 and competition assays for binding of biotinylated LPS. 1) . LPS from Escherichia coli J5 was purchased from Sigma-Aldrich Japan K.K. (Tokyo, Japan). Polyclonal rabbit antisera and monoclonal antibodies from mice (clone 1C7 and 6G3) against human LBP were purchased from HyCult Biotechnology BV (Uden, The Netherlands). Calcium and magnesium-free phosphate-buffered saline (PBS [-] ) was obtained from Invitrogen Corp. (Carlsbad, CA, USA). All chemicals used, purchased from standard suppliers, were reagent grade or better.
MATERIALS AND METHODS

Chemicals
Animals
Female C57BL/6 mice were purchased from Charles River Laboratories (Wilmington, MA, USA). The LBP knockout (KO) BALB/c and C57BL/6 mice 28 were the kind gift of Dr M. J. Fenton. All animal experiments were conducted in accordance with the ethical guidelines of Charles River Laboratories.
Plasma isolation
Human blood was drawn from healthy Japanese volunteers after obtaining informed consent. Blood was treated with heparin to prevent clotting. Plasma was isolated from blood by centrifugation (1500 g for 10 min). The isolated plasma was stored at 4°C just prior to use. Plasma was isolated from male BALB/c wild-type and LBP KO mice from heparinized blood by centrifugation and stored at -20°C until use. For plasma clearance studies, plasma was isolated from the blood of female wildtype and LBP KO C57BL/6 mice after administration of E5564.
Surface plasmon resonance
We used the Biacore2000 (Biacore K.K.; Tokyo, Japan) and Biacore F1 Pioneer sensor chips to study the interaction between LBP and either E5564 or LPS. Amine coupling was used to immobilize LBP on the sensor chip according to the manufacturer's instructions. Remaining amine reactive moieties on the sensor surface were blocked with ethanolamine. PBS(-) served as the running buffer. Three washes with 10 mM sodium hydroxide completely removed the bound E5564 or LPS from the immobilized LBP on the sensor chip.
E5564 inhibition of biotinylated LPS binding to LBP
An Endoblock test kit, used according to the manufacturer's instructions (HyCult Biotechnology BV), assessed the inhibition of biotinylated-LPS binding to LBP by E5564. Polymyxin B and anandamide were used as positive and negative controls, respectively.
GFC for plasma samples
To examine the interaction of E5564 with plasma components, we incubated [
14 C]-E5564 (6 µg/ml) in heparinized plasma. We then analyzed the mixture by gel filtration on a TSK-gel G3000SWXL (7.8 mm × 30 cm; Tosoh; Tokyo, Japan) column pumped with 1 ml/min of a 50 mM phosphate buffer with 150 mM sodium chloride (pH 7.4) at ambient temperature. The HPLC system contained a Waters Model 600E multisolvent delivery system and a Waters 717 autosampler (Nihon Waters K.K.; Tokyo, Japan) equipped with a Ramona92 radiodetector (Raytest; Isotopenmessgeräte GmbH; Straubenhardt, Germany) and a Waters 486 Tunable Absorbance Detector (Waters).
We measured cholesterol and albumin concentrations in total plasma and the fractions separated by gel filtration with the Cholesterol E-Test Wako 29 and the Albumin B-Test Wako 30 kits (Wako Pure Chemicals, Osaka, Japan), respectively. Concentrations of apoA-I and apoB were measured by sandwich ELISA. Briefly, 96-well microtiter plates (Costar, 9018, Corning, NY, USA) were coated with apoA-I-specific (Calbiochem, Darmstadt, Germany) or apoB-specific monoclonal antibodies (Calbiochem), then blocked with the Brock Ace (Dainippon Pharma, Osaka, Japan). After the addition of samples to each well, apoA-I-specific polyclonal sheep IgG-horseradish peroxidase (HRP)-conjugated (The Binding Site, Birmingham, UK) or apoB-specific sheep IgG-HRP-conjugated (The Binding Site) antibodies were used to detect bound apoA-I and apoB. After washing, TMB Microwell Peroxidase Substrate (BioFX, Rotterdam, Netherlands) was added. After the addition of 1 M HCl, we measured the absorbance at 450 nm. The concentrations of apoA-I and apoB were expressed as the magnitude of OD at 450 nm. The values obtained by ELISA were linear over concentrations ranging from 10-1000 ng/ml and 10-4000 ng/ml for apoA-I and apoB, respectively. The samples in these assays corresponded to concentrations within the linear range.
To study the effect of anti-LBP polyclonal or monoclonal antibodies on the binding of E5564 to lipoproteins, anti-LBP antibodies were premixed with human plasma (1:9, v/v) and incubated for 15 min at 37°C. The mixed plasma samples were then used for further assays.
Heparin-manganese precipitation of plasma sample
After incubation of human plasma with [
14 C]-E5564 (5 µg/ml or designated concentrations) for up to 2 h at 37°C, 25 µl of the plasma sample was mixed with 1.0 ml of the heparin-manganese salt solution that served as the precipitation reagent solution for the HDL Cholesterol Test Wako kit (Wako Pure Chemicals). 31 Following a 10-min incubation at either room temperature or 4°C, samples were centrifuged at 1500 g for 15 min to precipitate the non-HDL lipoprotein fraction. A TRI-CARB 2700TR liquid scintillation counter (Perkin-Elmer; MA, USA) was used to measure radioactivity. Concurrently, we also performed gel filtration chromatography on the same plasma sample.
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Plasma clearance in LBP knockout mice
After intravenous administration of E5564 to female C57BL/6 wild-type or LBP KO mice via the tail vein at a dose of 0.5 mg/kg (n = 3 per each time point), plasma was isolated at 2, 5, 15, and 30 min, and 1 and 2 h post-dosage, then stored at -20°C until analysis. Quantification of E5564 in the plasma samples was performed using previously published methods. 13 The range of concentrations accurately determined by this method ranges from 30 ng/ml to 20 µg/ml.
Data treatment and statistics
Sensorgrams and elution profiles in this study were performed at least twice to confirm reproducibility, and representative results are shown. For inhibition of biotinylated-LPS binding, heparin-manganese precipitation and plasma clearance of E5564 in mice, mean ± SD values of triplicate experiments were calculated. The statistical significance of differences between two means were evaluated by paired t-test or Tukey's test, and P values < 0.05 were considered significant. In concentration dependency of E5564 binding to HDL determined by heparin-manganese precipitation, linear regression analysis was also performed.
RESULTS
Surface plasmon resonance study
The binding affinity of LPS, isolated from E. coli J5, and E5564 for LBP were evaluated by surface plasmon reso-188 Kaneko, Ueda, Kawata, Ishizaka, Yoshimura nance (SPR) using Biacore2000. We obtained sensorgrams for 1 µg/ml of LPS and for 5 µg/ml of E5564 with LBP immobilized at approximately 1200 RU on the F1 sensor chip (Fig. 2) . The sensorgram for LPS demonstrates that LPS binds to immobilized LBP to form stable complexes; a similar sensorgram was obtained for E5564. These results indicate that E5564 binds to LBP in a similar fashion as LPS.
We evaluated the effect of pre-mixing LBP with E5564 in the injection fluid on the binding of E5564 to immobilized LBP. The interaction between E5564 and immobilized LBP was inhibited in an LBP concentration-dependent manner; 500 ng/ml LBP completely inhibited increases in the resonance signal (Fig. 3a) . These results imply a similar binding of E5564 to immobilized or free LBP. We also assessed the effects of the most abundant plasma protein, albumin, on the binding of E5564 to immobilized LBP (Fig. 3b) . The results demonstrate that complete inhibition of E5564-LBP binding occurs at 50 µg/ml HSA, 100-fold greater concentrations than the concentration of LBP needed to inhibit E5564 binding completely. As both LPS and E5564 form micelles, the precise association and dissociation constants for LBP and either LPS or E5564 could not be determined.
Inhibition of biotinylated LPS binding to LBP
To assess if the E5564 binding site on LBP is the same as that for LPS, we examined the inhibition of biotinylated LPS binding to immobilized LBP by E5564. E5564 reduced the binding of biotinylated LPS to immobilized LBP in a concentration-dependent manner (IC 50 , 0.20 µM; Fig. 4) . The results indicate that E5564 inhibits the binding of biotinylated LPS to LBP.
Gel filtration chromatogram for E5564 in human plasma
To determine the binding of E5564 to lipoproteins under simulated physiological conditions, [
14 C]-E5564 (6 µg/ml) was incubated at 37°C with fresh samples of human heparinized plasma for up to 45 min. After incubation, we assessed the binding profile of E5564 to lipoproteins in plasma samples immediately analyzed by GFC (Fig. 5a ). In unincubated plasma samples, only one 14 C]-E5564 (6 µg/ml) was added to the plasma samples and incubated at 37°C for up to 45 min. After application of these samples to a gel filtration column, the radioactivity derived from [ 14 C]-E5564 was monitored by an on-line RI detector. The data are representative of three independent experiments. radioactive peak was found 5 min after the start of the run. As cholesterol and Apo-B are found at 5 min after injection of human plasma, non-HDL lipoproteins, LDL, VLDL and chylomicron elute at this time point (data not shown). After injection of [ 14 C]-E5564 alone, no radioactivity was found at 5 min after injection, and low levels of radioactivity, which did not form a peak shape, continuously eluted from the column (data not shown). Thus, the radioactive peak found 5 min after injection suggests that E5564 distributed to the non-HDL lipoprotein fraction of plasma just after mixing.
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Gel filtration chromatograms of human plasma incubated with [ 14 C]-E5564 (6 µg/ml) at 37°C revealed that a radioactive peak found at 8 min increased in magnitude with incubation time, concomitant with decreases in the peak at 5 min. As cholesterol and Apo-AI eluted at 8 min after injection of human plasma, HDL eluted at this time point (data not shown). This radioactive peak found at 8 min after injection suggests that E5564 increasingly bound to HDL in the plasma with increasing incubation at 37°C. These results indicate that [ 14 C]-E5564 initially distributes to non-HDL proteins and subsequently dissociates from non-HDL lipoproteins to bind to HDL. In these chromatograms, no radioactivity was found 9 min after injection in the albumin elution time point, indicating that E5564 does not bind to albumin in the plasma to any appreciable extent. The elution profiles of albumin, cholesterol, Apo-AI, and Apo-B after incubation with E5564 at 37°C were identical to those in blank plasma (data not shown). 14 C]-E5564 to HDL in human plasma was found at higher concentrations of E5564 with statistically significant linearity by 1-h incubation 37°C (see Fig. 7) ; however, the distribution ratio of E5564 to HDL after a 2-h incubation at 37°C was concentration-independent suggesting that the binding capacity of HDL for E5564 exceeds the amount of E5564 added (13.87 µg/ml) but that delivering of E5564 to HDL may depend on plasma constituents that are limiting (see Fig. 7 ).
Ability of anti-LBP antibodies to block E5564 binding
To determine the role of LBP in the binding of E5564 to lipoproteins, we evaluated the ability of antibodies against human LBP to block E5564 binding in human plasma. After incubation of [ 14 C]-E5564 in plasma in the absence or presence of polyclonal anti-LBP antibodies for up to 45 min at 37°C, plasma samples were analyzed by GFC (Fig. 5b) 
Gel filtration chromatogram for E5564 in mouse plasma
As it is possible that the titer of the antibody against LBP was not large enough to inhibit the binding of E5564 in the plasma completely, we evaluated the binding profiles of [ 14 C]-E5564 in plasma obtained from male BALB/c wild-type or LBP KO mice. Following incubation of 6 µg/ml [ 14 C]-E5564 with plasma from wild-type or LBP KO mice for up to 15 min at 37°C, plasma samples were analyzed by gel-filtration chromatography (Fig. 8) .
In the wild-type mouse plasma, [ 14 C]-E5564 initially distributed to non-HDL lipoprotein fractions, then dissociated to subsequently bind to HDL, similar to observations of human plasma. In the LBP KO mouse plasma, a large portion of [
14 C]-E5564 bound to HDL just after preparation, while a fraction of [
14 C]-E5564 in the HDL fraction increased with incubation time. Although the initial binding profile of [
14 C]-E5564 in the LBP KO mouse plasma differed from that of wild-type mouse plasma, the binding of E5564 to HDL occurred independently of LBP, coinciding with the human data.
Plasma clearance in LBP KO mice
To evaluate the role of LBP in plasma clearance of E5564 in mice, we evaluated the plasma concentration profiles of E5564 in both female C56BL/6 wild-type and LBP KO mice after intravenous administration of E5564 (0.5 mg/kg) at up to 2 h after administration. The plasma concentration of E5564 in LBP KO mice was similar to that seen in wild-type mice (Fig. 9) . These results suggest that LBP does not play a major role in plasma clearance of E5564 in mice.
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DISCUSSION
Two approaches were considered to evaluate the interaction between E5564 and LBP by Biacore. One, utilized in this study, immobilizes LBP, while the other immobilizes E5564 onto a hydrophobic surface sensorchip using E5564-embedded POPC liposomes. Only weak interactions between E5564 and LBP could be detected in the latter case (data not shown), because the binding domain of E5564 used to bind to LBP might be used for immobilization. As the binding ability of immobilized LBP to E5564 was much higher than that found in the latter case, immobilization of LBP is more suitable for the evaluation of this interaction. As E5564 forms miceller superstructures similar to those of LPS, precise binding parameters for E5564 and LBP interactions could not be determined.
Additional SPR studies using immobilized HSA and the gel-filtration chromatogram of [ 14 C]-E5564 in a HSA solution and lipoprotein deficient-plasma demonstrated that E5564 bound to albumin in a manner similar to LPS (data not shown). 32, 33 In human and mouse plasma, however, no radioactivity derived from [ 14 C]-E5564 could be found in the elution point of albumin in the chromatogram (Figs 5a   and 8 ). These results suggest that the binding affinity of E5564 for albumin was much lower than that observed for lipoproteins. While LPS containing long polysaccharide chains binds to albumin in human serum, 24 the highly hydrophobic LPS molecules with shorter polysaccharide chains purified from E. coli J5 and Salmonella serovar typhimurium ReLPS do not bind as strongly to albumin and possess a greater affinity for lipoproteins. 25 E5564, an analogue of lipid A, has no polysaccharide chain (Fig. 1) ; consequently, the hydrophobicity of E5564 is much higher than that of either E. coli and S. typhimurium LPS. Thus, it is likely that the binding affinity of E5564 for albumin is significantly lower than the affinity of both E. coli and S. typhimurium lipopolysaccharides for albumin.
As E5564 inhibited the binding of biotinylated-LPS to LBP in a concentration-dependent manner and demonstrated LPS-like binding to immobilized LBP in SPR studies, E5564 likely binds to LBP in a similar manner as LPS. However, the distribution and binding of E5564 to lipoproteins does not appear to require LBP in the plasma.
The advantages of the HPLC-GFC over ultracentrifugation are speed and reproducibility: this technique takes only 15 min to complete, much faster than ultracentrifugation assays typically requiring 18 h or more. The distribution and binding of E5564 to plasma lipoproteins might progress during ultracentrifugation, as the binding of E5564 to lipoproteins in plasma reaches steady-state levels after a 2 h incubation at 37°C.
As the binding affinity of E5564 to LBP is only approximately 100-fold higher than that to albumin, a highly abundant plasma protein, the possibility remains that the binding affinity of E5564 to LBP in plasma is not high; therefore, antibody to LBP does not inhibit delivery of E5564 to HDL (Fig. 5b) . In addition, at the concentration of E5564 used, E5564 binding to LBP may saturate the binding sites LBP thus diminishing the activity of the anti-LBP antibody. LBP does not appear to have a major role in E5564 distribution and binding to lipoproteins in the plasma in the range of 1-10 µg/ml of E5564, the expected clinically efficacious concentration. As LPS binds to non-HDL lipoproteins in LBP-depleted serum, 34 LBP-independent interactions with non-HDL lipoproteins are likely common features of LPS and lipid A analogues. Levels et al. 25 reported that the binding kinetics of LPS to lipoproteins are chemotype-dependent. More highly hydrophobic LPS molecules with shorter polysaccharide chains have a greater apparent affinity for the lipoprotein phospholipid layer. Therefore, the LBP-independent distribution of E5564 to the non-HDL lipoprotein fraction probably results from the hydrophobic nature of E5564. The extensive distribution of E5564 to non-HDL lipoproteins at 4°C suggests a dispersion-like process, which is insensitive to temperature. This mechanism induces a rapid interaction of E5564 with lipoproteins, contributing to the slow clearance of E5564; non-binding LPS and/or lipid A can interact with scavenger receptors to be readily cleared. 35 LBP plays a major role in the binding of either LPS or lipid A to HDL. 20, [36] [37] [38] Our data demonstrate that binding of E5564 to HDL does not require LBP. As the binding of E5564 to HDL is concentration-dependent, an additional plasma protein, independent of LBP, may mediate E5564 transfer from non-HDL proteins to HDL. The details of this mechanism, however, are not yet clear.
The quantities of apoprotein AI, AII, B, C, and E in the LBP KO mouse plasma does not differ from that in wild-type mouse plasma (data not shown), suggesting that lipoprotein compositions in plasma are similar for both mice. Thus, the reason underlying the differences in binding rates of E5564 between wild-type and LBP KO mouse plasma remains unclear. The binding of E5564 to HDL in plasma occurred independently of LBP binding in mouse plasma.
In patients with severe sepsis, the concentrations of LBP in the plasma are up-regulated. As LBP does not play a major role in the plasma clearance of E5564, the increases in plasma LBP concentrations mediated by severe infection do not appear to affect E5564 plasma clearance. Therefore, the pharmacokinetics of E5564 is not influenced by the severity of infection, which is important not only for studies of pharmacokinetics, but also for understanding the potential and efficacy of this drug as a treatment for severe sepsis.
